Who are Belimumab plus Early Vaccination's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Belimumab Injection [Benlysta], Belimumab (GSK1550188), Belimumab Injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/belimumab-plus-early-vaccination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Belimumab plus Early Vaccination — Competitive Intelligence Brief

Belimumab plus Early Vaccination (Belimumab plus Early Vaccination) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: BLyS inhibitor monoclonal antibody. Area: Immunology.

marketed BLyS inhibitor monoclonal antibody B-lymphocyte stimulator (BLyS) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Belimumab plus Early Vaccination (Belimumab plus Early Vaccination) — Human Genome Sciences Inc., a GSK Company. Belimumab inhibits B-lymphocyte stimulator (BLyS) to reduce autoreactive B cells, combined with early vaccination to enhance immune response.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Belimumab plus Early Vaccination TARGET	Belimumab plus Early Vaccination	Human Genome Sciences Inc., a GSK Company	marketed	BLyS inhibitor monoclonal antibody	B-lymphocyte stimulator (BLyS)
Belimumab Injection [Benlysta]	Belimumab Injection [Benlysta]	National University Hospital, Singapore	marketed	BLyS inhibitor monoclonal antibody	B-lymphocyte stimulator (BLyS/BAFF)
Belimumab (GSK1550188)	Belimumab (GSK1550188)	GlaxoSmithKline	marketed	BLyS inhibitor monoclonal antibody	BLyS (B-lymphocyte stimulator / BAFF)
Belimumab Injection	Belimumab Injection	Nanjing University School of Medicine	phase 3	BLyS inhibitor monoclonal antibody	BLyS (B-lymphocyte stimulator / BAFF)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (BLyS inhibitor monoclonal antibody class)

GlaxoSmithKline · 1 drug in this class
Human Genome Sciences Inc., a GSK Company · 1 drug in this class
Nanjing University School of Medicine · 1 drug in this class
National University Hospital, Singapore · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Belimumab plus Early Vaccination — Competitive Intelligence Brief. https://druglandscape.com/ci/belimumab-plus-early-vaccination. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab